Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
Holding SPRY?
Track your performance easily
SPRY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.76 - $18.51
Previous Close$17.49
Volume1.71M
Average Volume (3M)1.17M
Market Cap
$1.70B
Enterprise Value$1.48B
Total Cash (Recent Filing)$218.74M
Total Debt (Recent Filing)$160.00K
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Nov 13, 2024EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding96,941,609
10 Day Avg. Volume1,310,453
30 Day Avg. Volume1,174,323
Standard Deviation0.21
R-Squared0.04
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)7.48
Price to Sales (P/S)3391.02
Price to Cash Flow (P/CF)-58.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.95K
Enterprise Value/Gross Profit49.23K
Enterprise Value/Ebitda-26.04
Forecast
1Y Price Target
$25.50Price Target Upside53.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
ARS Pharmaceuticals News
PremiumCompany Announcements
ARS Pharmaceuticals’ Strong Q3 2024 Highlights
Ownership Overview
61.32% Insiders
7.88% Mutual Funds
2.40% Other Institutional Investors
20.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $3.76 and its highest was $18.51 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
Currently, no data Available
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Nov 13, 2024 which is 8 days ago.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Aug 06, 2024. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.019.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -$0.14.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 96,941,610 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went down -2.249%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Among the largest hedge funds holding ARS Pharmaceuticals’s share is Deerfield Management Company, LP. It holds ARS Pharmaceuticals’s shares valued at 94M.
---
ARS Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.50 (53.52% Upside)
$25.50 (53.52% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 33.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 14.8%
Last 30 Days ▲ 14.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
368.90%
12-Months-Change
Fundamentals
Return on Equity
-19.34%
Trailing 12-Months
Asset Growth
-14.22%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
---
SPRY Stock 12 Month Forecast
Average Price Target
$25.50
▲(53.52% Upside)
Technical Analysis
Best Analysts Covering SPRY
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+125.90%
assigned a buy rating 9 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +125.90% per trade.
---